Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector (Q39877530)

15 September 2017

Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector (English)

1 reference

Rift Valley fever phlebovirus

15 September 2017

0 references

0 references

1 reference

1 reference

Rift Valley fever virus

object named as

Rift Valley fever virus

1 reference

J Kortekaas

1

1 reference

15 September 2017

S M de Boer

2

1 reference

15 September 2017

J Kant

3

1 reference

15 September 2017

R P M Vloet

4

1 reference

15 September 2017

A F G Antonis

5

1 reference

15 September 2017

R J M Moormann

6

1 reference

15 September 2017

language of work or name

English

0 references

publication date

29 April 2010

1 reference

15 September 2017

1 reference

15 September 2017

28

1 reference

15 September 2017

27

1 reference

15 September 2017

4394-4401

1 reference

New vectors of Rift Valley fever in West Africa

15 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Pathological studies on postvaccinal reactions of Rift Valley fever in goats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

7 January 2021

Rift Valley fever virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Neutralizing antiviral B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Genome replication of Newcastle disease virus: involvement of the rule-of-six

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Recombinant nucleocapsid-based ELISA for detection of IgG antibody to Rift Valley fever virus in African buffalo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Recombinant Newcastle disease virus as a vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Baculovirus as versatile vectors for protein expression in insect and mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Nonsegmented negative-strand viruses as vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Experimental infection of calves with Newcastle disease virus induces systemic and mucosal antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Newcastle disease virus V protein is a determinant of host range restriction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Analysis of the interferons induced in mice in vivo and in macrophages in vitro by Newcastle disease virus and by polyinosinic-polycytidylic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Interferons alpha and beta as immune regulators--a new look

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.048

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.04.048

1 reference

15 September 2017

1 reference